• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 20, 2019

View Archived Issues

Nabriva scores FDA approval for new CABP therapy, lefamulin

Nabriva Therapeutics plc has gained FDA approval of NDAs for both I.V. and oral formulations of lefamulin, a semisynthetic antibiotic for the treatment of community-acquired bacterial pneumonia (CABP) it will market as Xenleta. It's the first pleuromutilin for systemic use in humans to win FDA approval, leading the first new class of antibiotics for CABP in almost 20 years. Read More

Some Rx pricing remedies could be treating the patient in the wrong setting

In a second opinion of sorts, a government report suggests that some of the drug pricing remedies U.S. lawmakers and the Trump administration have proposed could be the right prescription for the wrong setting, especially when it comes to pharmacy benefit managers (PBMs). Read More

STAR potential: Frontier applies for $286M IPO and listing on Shanghai board

BEIJING – Look out, Hong Kong Stock Exchange (HKEX). Chinese pre-profit biotech startups are now starting to apply for listing on Shanghai's sci-tech innovation board known as the STAR, with the latest application filed by HIV drugmaker Frontier Biotechnologies Inc., of Nanjing. Read More

Results from Kalytera's CBD phase II trial in GVHD boost stock; gearing up for phase III

Interim results from Kalytera Therapeutics Inc.'s phase II open-label study of multiple doses of cannabidiol (CBD) in preventing acute graft-vs.-host disease (GVHD) were positive enough to persuade the company to skip enrolling the high-dose cohort and move directly to a phase III registration study. Read More

Old made new: Alkahest plasma fraction research entering another phase II

Chief Commercial and Strategy Officer Elizabeth Jeffords told BioWorld that the endpoints in Alkahest Inc.'s just-begun phase II trial with human plasma fraction GRF-6021 will not only test how well patients bounce back from hip or knee arthroplasty but "could absolutely support the work in cognitive and neurodegenerative indications as well," where data rolled out earlier this month. Read More

Vanderbilt researchers weaponize white blood cells to track and kill cancer cells

Biomedical researchers at Vanderbilt University have created "cellular soldiers" that use the body's innate defenses to eliminate cancer cells dispersed during surgery. When used perioperatively, the attack cells kill stray cancer cells and keep them from forming metastases. Read More

Other news to note

Generex Biotechnology Corp., of Miramar, Fla., said it acquired an additional 38% of Olaregen Therapeutix Inc., of New York, for total ownership of approximately 99% through a cashless exchange of Generex stock (OTCQB:GNBT) at $2.50 per share. Read More

Regulatory front

The FDA's Center for Drug Evaluation and Research (CDER) is looking for five drug companies to participate in a Fit for Use pilot program to test the processing and analysis of nonclinical study data provided electronically for the Clinical Data Interchange Standards Consortium (CDISC) using the SEND 3.1 format.  Read More

Financings

Ico Therapeutics Inc., of Vancouver, British Columbia, issued 41.2 million units pursuant to a nonbrokered private placement.  Read More

Clinical data for Aug. 19, 2019

Read More

Regulatory actions for Aug. 19, 2019

Read More

Juvenescence adds $100M in series B for anti-aging investee companies

LONDON – Juvenescence Ltd. has closed a $100 million series B round, providing ample scope for the anti-aging specialist to make further investments in the band of companies it is supporting to develop products that aim to increase the healthy lifespan of humans. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe